Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands

Annals of Oncology

Volumn 18, Issue 6, 2007, Pages 1110-1116

  de Vries, E ^a,b   Houterman, S ^b   Janssen Heijnen, M L G ^b   Nijsten, T ^a   van de Schans, S A M ^b   Eggermont, A M M ^a   Coebergh, J W W ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Eindhoven Cancer Registry   (Netherlands)

Author keywords

Crude survival; Cutaneous malignant melanoma; Period analysis; Population based; Relative survival

Indexed keywords

ADULT; AGE; ARTICLE; CANCER REGISTRY; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; NETHERLANDS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE;

FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INCIDENCE; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 34447298882     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm087     Document Type: Article

References (30)

1. Smith JAE, Whatley PM, Redbum JC, Group EW. Improving survival of melanoma patients in Europe since 1978. Eur J Cancer 1998; 34: 2197-2203.
2. MacKie RM, Bray CA, Hole DJ et al. Incidence of and survival from malignant melanoma in Scotland: An epidemiological study. Lancet 2002; 360: 587-591.
3. Kölmel KF, Kulle B, Lippold A, Seebacher C. Survival probabilities and hazard functions of malignant melanoma in Germany 1972-1996, an analysis of 10433 patients. Evolution of gender differences and malignancy. Eur J Cancer 2002; 38: 1388-1394.
4. Sant M, Aareleid T, Berrino F et al. EUROCARE-3: Survival of cancer patients diagnosed 1990-94-results and commentary. Ann Oncol 2003; 14 (Suppl 5): V61-V118.
5. Kemeny MM, Busch E, Stewart AK, Menck HR. Superior survival of young women with malignant melanoma. Am J Sung 1998; 175: 437-444.
6. Gillgren P, Brattstrom G, Frisell J et al. Effect of primary site on prognosis in patients with cutaneous malignant melanoma. A study using a new model to analyse anatomical locations. Melanoma Res 2005; 15: 125-132.
7. Downing A, Newton-Bishop JA, Forman D. Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in relation to stage of disease, 1993-2003. Br J Cancer 2006; 95 (1): 91-95.
8. Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer 1996; 78: 2004-2010.
9. Brenner H, Hakulinen T. Long-term cancer patient survival achieved by the end of the 20th century: Most up-to-date estimates from the nationwide Finnish cancer registry. Br J Cancer 2001; 85: 367-371.
10. Brenner H, Soderman B, Hakulinen T. Use of period analysis for providing more up-to-date estimates of long-term survival rates: Empirical evaluation among 370,000 cancer patients in Finland. Int J Elpidemiol 2002; 31: 456-462.
11. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: A period analysis. Lancet 2002; 360: 1131-1135.
12. Houterman S, Janssen-Heijnen ML, van de Poll-Franse LV et al. Higher long-term can,cer survival rates in southeastern Netherlands using up-to-date period analysis. Ann Oncol 2006; 17: 709-712.
13. dos Santos Silva I. Cancer Epidemiology: Principles and Methods. Barcelona, Spain: THAY S.L 1999.
14. Hakulinen T, Abeywickrama KH. A computer program package for relative survival analysis. Comput Programs Biomed 1985; 19: 197-207.
15. Greenwood M. A Report on the Natural Duration of Cancer. London: Ministry of Health HMSO 1926.
16. Brenner H, Gefeller O. Deriving more up-to-date estimates of long-term patient survival. J Clin Epidemiol 1997; 50: 211-216.
17. Brenner H, Gefeller O, Hakulinen T. Period analysis for up to date cancer survival data: Theory, empirical evaluation, computational realisation and applications. Eur J Cancer 2004; 40: 326-335.
18. Brenner H, Gefeller O, Hakulinen T. A computer program for period analysis of cancer patient survival. Eur J Cancer 2002; 38: 690-695.
19. Kavanagh D, Hill AD, Djikstra B et al. Adjuvant therapies in the treatment of stage II and III malignant melanoma. Surgeon 2005; 3: 245-256.
20. Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005; 6: 185-193.
21. Devos SA, Baeyens K, Van Hecke L. Sunscreen use and skin protection behavior on the Belgian beach. Int J Dermatol 2003; 42: 352-356.
22. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: Population based ecological study. Br Med J 2005; 331 (7515): 481.
23. de Vries E, Coebergh JW. Melanoma incidence has risen in Europe. Br Med J 2005; 331: 698.
24. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634.
25. Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR). Cancer survival in Australia, 2001. Part 1: National summary statistics. AIHW cat. no CAN 13. Canberra, Australia: Australian Institute of Health and Welfare 2001.
26. Ries L, Harkins D, Krapcho M et al. SEER Cancer Statistics Review, 1975-2003. National Cancer Institute. Bethesda, MD 2006.
27. Gimotty PA, Botbyl J, Soong SJ, Guerry D. A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2005; 23: 8065-8075.
28. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
29. de Vries E, Houterman S, Coeberg JW. Different site distribution does not explain gender differences in survival of melanoma. BMJ 2006; http://bmj.bmjjournals.com/cgi/eletters/332/7548/987#135142 (16 March 2007, date last accessed).
30. Scoggins CR, Ross MI, Reintgen DS et al. Gender-related differences in outcome for melanoma patients. Ann Surg 2006; 243: 693-698; discussion 698-700.